Research & Development
The US FDA provides update of COVID-19 actions
10 August 2020 -

Public health agency the US Food and Drug Administration (FDA) stated on Friday that it has currently authorized 207 tests under EUAs, including 168 molecular tests, 37 antibody tests and two antigen tests, in the ongoing response to the COVID-19 pandemic.

On 6 August 2020, the agency revoked the emergency use authorization (EUA) for Autobio Diagnostics Co Ltd's Anti-SARS-CoV-2 Rapid Test, a SARS-CoV-2 antibody test, due to performance concerns with the accuracy of the test.

In a joint statement with the Federal Trade Commission, the agency has issued a warning letter to Canadian Chaga for selling fraudulent COVID-19-related products as well as with misleading content that its products can mitigate, prevent, treat, diagnose, or cure COVID-19 in people. There are currently no FDA-approved products to prevent or treat COVID-19.

In conjunction, the agency has updated its Coronavirus Treatment Acceleration Programme (CTAP) webpage with new metrics and FAQs. About 570+ drug development programmes are in the planning stages and 270+ trials have been reviewed as of 31 July 2020.



Related Headlines